ACC-001 3 μg/ QS-21 50 μg [clinicaltrials_resource:00376e207950d5062dbd59661625aa0d]
intervention [clinicaltrials_vocabulary:intervention]
ACC-001 3 μg/ QS-21 50 μg [clinicaltrials_resource:00376e207950d5062dbd59661625aa0d]
Bio2RDF identifier
00376e207950d5062dbd59661625aa0d
Bio2RDF namespace
clinicaltrials_resource
Bio2RDF uri
http://bio2rdf.org/clinicaltrials_resource:00376e207950d5062dbd59661625aa0d
arm group [clinicaltrials_vocabulary:arm-group]
intervention desc [clinicaltrials_vocabulary:intervention-desc]
ACC-001 3 μg/ QS-21 50 μg IM on day 1, month 1, month 3, month 6, month 12, and month 18
intervention name [clinicaltrials_vocabulary:intervention-name]
ACC-001 3 μg/ QS-21 50 μg
other name [clinicaltrials_vocabulary:other-name]
Vanutide Cridificar
identifier
clinicaltrials_resource:00376e207950d5062dbd59661625aa0d
title
ACC-001 3 μg/ QS-21 50 μg
@en
type
label
ACC-001 3 μg/ QS-21 50 μg [clinicaltrials_resource:00376e207950d5062dbd59661625aa0d]
@en